The Use of Specialized Pro-Resolving Mediators in Biomaterial-Based Immunomodulation
Source abstract
Abstract
The implantation of a biomaterial will lead to the immediate onset of an acute inflammatory response, which is of key importance in shaping the quality of the repair process. However, the return to homeostasis is critical to prevent a chronic inflammatory response that may impair the healing process. The resolution of the inflammatory response is now recognized as an active and highly regulated process, being described as specialized immunoresolvents that have a fundamental role in the termination of the acute inflammatory response. These mediators collectively coined as specialized pro-resolving mediators (SPMs) are a family of endogenous molecules that include lipoxins (Lx), resolvins (Rv), protectins (PD), maresins (Mar), Cysteinyl-SPMs (Cys-SPMs) and n-3 docosapentaenoic acid-derived SPMs (n-3 DPA-derived SPMs). SPMs have important anti-inflammatory and pro-resolutive actions such as decreasing the recruitment of polymorphonuclear leukocytes (PMNs), inducing the recruitment of anti-inflammatory macrophages, and increasing macrophage clearance of apoptotic cells through a process known as efferocytosis. Over the last years, the trend in biomaterials research has shifted towards the engineering of materials that are able to modulate the inflammatory response and thus stimulate appropriate immune responses, the so-called immunomodulatory biomaterials. These materials should be able to modulate the host immune response with the aim of creating a pro-regenerative microenvironment. In this review, we explore the potential of using of SPMs in the development of new immunomodulatory biomaterials and we propose insights for future research in this field.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Fatty Acid Research and Health · Advanced Glycation End Products research · Neonatal Respiratory Health Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
i3S—Instituto de Inovação e Investigação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-125 Porto, Portugal
INEB—Instituto de Engenharia Biomédica, Rua Alfredo Allen, 208, 4200-125 Porto, Portugal
ICBAS—Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
Funding
Norte Regional Operational Program-Structured R&D&I Projects—Unorte.pt.
References (99)
Show source-provided references
1. Biological responses to materials10.1146/annurev.matsci.31.1.81 ↗
2. Foreign Body Reaction to Implanted Biomaterials and Its Impact in Nerve Neuroprosthetics10.3389/fbioe.2021.622524 ↗
3. Prevention of the foreign body response to implantable medical devices by inflammasome inhibition10.1073/pnas.2115857119 ↗
4. Inflammatory response to implants10.1097/00002480-198804000-00005 ↗
5. Foreign body reaction to biomaterials10.1016/j.smim.2007.11.004 ↗
6. Christo, S.N., Diener, K.R., Bachhuka, A., Vasilev, K., and Hayball, J.D. (2015). Innate Immunity and Biomaterials at the Nexus: Friends or Foes. Biomed. Res. Int., 2015.10.1155/2015/342304 ↗
7. Immune response to biologic scaffold materials10.1016/j.smim.2007.11.003 ↗
8. Immune responses to implants—A review of the implications for the design of immunomodulatory biomaterials10.1016/j.biomaterials.2011.05.078 ↗
9. DAMPs, PAMPs and alarmins: All we need to know about danger10.1189/jlb.0306164 ↗
10. Biocompatibility of implants: Lymphocyte/macrophage interactions10.1007/s00281-011-0244-1 ↗
11. Expanded applications, shifting paradigms and an improved understanding of host-biomaterial interactions10.1016/j.actbio.2012.10.025 ↗
12. Macrophage polarization: An opportunity for improved outcomes in and regenerative medicine10.1016/j.biomaterials.2012.02.034 ↗
13. Macrophage phenotypes in tissue repair and the foreign body response: Implications for biomaterial-based regenerative medicine strategies10.1016/j.actbio.2021.03.038 ↗
14. Resolution of inflammation: An organizing principle in biology and medicine10.1016/j.pharmthera.2021.107879 ↗
15. Cellular resolution of inflammation—Catabasis10.1111/j.1524-475X.2011.00754.x ↗
16. The Atlas of Inflammation Resolution (AIR)10.1016/j.mam.2020.100894 ↗
17. Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes10.1073/pnas.81.17.5335 ↗
18. Is Resolution the End of Inflammation?10.1016/j.molmed.2019.01.006 ↗
19. Lipoxins: Resolutionary road10.1111/j.1476-5381.2009.00386.x ↗
20. Natural resolution of inflammation10.1111/prd.12034 ↗
21. Resolution of inflammation: State of the art, definitions and terms10.1096/fj.06-7227rev ↗
22. Pro-resolving lipid mediators are leads for resolution physiology10.1038/nature13479 ↗
23. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution10.1016/j.smim.2015.03.004 ↗
24. The regulatory effect of specialized pro-resolving mediators on immune cells10.1016/j.biopha.2022.113980 ↗
25. Specialized pro-resolving mediators as modulators of immune responses10.1016/j.smim.2022.101605 ↗
26. Resolution of inflammation: The beginning programs the end10.1038/ni1276 ↗
27. Recent advances in the chemistry and biology of anti-inflammatory and specialized pro-resolving mediators biosynthesized from n-3 docosapentaenoic acid10.1016/j.bmcl.2017.03.079 ↗
28. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing10.1084/jem.192.8.1197 ↗
29. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways10.1146/annurev.immunol.25.022106.141647 ↗
30. Lipoxin and Aspirin-Triggered Lipoxins10.1100/tsw.2010.113 ↗
31. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: Stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo10.1097/01.ASN.0000032417.73640.72 ↗
32. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine10.1042/cs0770195 ↗
33. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor10.1074/jbc.272.11.6972 ↗
34. Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages10.4049/jimmunol.164.4.1663 ↗
35. Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells10.1016/S0002-9440(10)62043-3 ↗
36. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype10.4049/jimmunol.1100225 ↗
37. Hsiao, H.M., Sapinoro, R.E., Thatcher, T.H., Croasdell, A., Levy, E.P., Fulton, R.A., Olsen, K.C., Pollock, S.J., Serhan, C.N., and Phipps, R.P. (2013). A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE, 8.10.1371/journal.pone.0058258 ↗
38. Resolvin D4 attenuates the severity of pathological thrombosis in mice10.1182/blood.2018886317 ↗
39. Specialized pro-resolving mediator network: An update on production and actions10.1042/EBC20200018 ↗
40. Resolvins and protectins in the termination program of acute inflammation10.1016/j.it.2007.02.007 ↗
41. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome10.1016/j.bbalip.2014.08.006 ↗
42. Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype10.1038/s41598-017-00103-0 ↗
43. Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGD(2) and DP(1) receptor in acute respiratory distress syndrome10.1016/j.intimp.2021.108348 ↗
44. PDX regulates inflammatory cell infiltration via resident macrophage in LPS-induced lung injury10.1111/jcmm.15679 ↗
45. Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis10.4049/jimmunol.1202743 ↗
46. Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions10.1084/jem.20081880 ↗
47. The Nuclear Receptor PPARgamma Controls Progressive Macrophage Polarization as a Ligand-Insensitive Epigenomic Ratchet of Transcriptional Memory10.1016/j.immuni.2018.09.005 ↗
48. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions10.1172/JCI129448 ↗
49. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain10.1096/fj.11-201442 ↗
50. Novel n-3 immunoresolvents: Structures and actions10.1038/srep01940 ↗
51. Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions10.1016/j.plipres.2022.101165 ↗
52. The novel lipid mediator PD1(n-3 DPA): An overview of the structural elucidation, synthesis, biosynthesis and bioactions10.1016/j.prostaglandins.2017.06.003 ↗
53. Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation10.1146/annurev-pharmtox-051821-042743 ↗
54. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice10.4049/jimmunol.1101305 ↗
55. Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease10.1007/s10571-022-01216-5 ↗
56. Resolution of acute inflammation in the lung10.1146/annurev-physiol-021113-170408 ↗
57. Low LXA4, RvD1 and RvE1 levels may be an indicator of the development of hypertension10.1016/j.plefa.2021.102365 ↗
58. Role of specialized pro-resolving lipid mediators and their receptors in virus infection: A promising therapeutic strategy for SARS-CoV-2 cytokine storm10.1007/s12272-020-01299-y ↗
59. Resolvin D1 protects periodontal ligament10.1152/ajpcell.00242.2012 ↗
60. Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy10.1016/j.ajpath.2017.01.018 ↗
61. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice10.1161/CIRCRESAHA.116.309492 ↗
62. Resolvin-D1 attenuation of angiotensin II-induced cardiac inflammation in mice is associated with prevention of cardiac remodeling and hypertension10.1016/j.bbadis.2021.166241 ↗
63. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis10.1172/jci.insight.85922 ↗
64. Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer’s disease10.1016/j.expneurol.2017.11.005 ↗
65. Resolvin D2 recovers neural injury by suppressing inflammatory mediators expression in lipopolysaccharide-induced Parkinson’s disease rat model10.1016/j.bbrc.2015.03.109 ↗
66. Valente, M., Dentoni, M., Bellizzi, F., Kuris, F., and Gigli, G.L. (2022). Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications. Molecules, 27.10.3390/molecules27154836 ↗
67. Deyama, S., Kaneda, K., and Minami, M. (2022). Resolution of depression: Antidepressant actions of resolvins. Neurosci. Res.10.1016/j.neures.2022.10.006 ↗
68. Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation10.1038/nri.2015.4 ↗
69. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema10.1111/j.1365-2133.2012.11177.x ↗
70. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness10.4049/jimmunol.178.1.496 ↗
71. Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells10.1126/science.aad9272 ↗
72. Engineering Immunomodulatory Biomaterials To Tune the Inflammatory Response10.1016/j.tibtech.2016.03.009 ↗
73. Modulating the foreign body response of implants for diabetes treatment10.1016/j.addr.2021.01.011 ↗
74. Macrophage plasticity and polarization in tissue repair and remodelling10.1002/path.4133 ↗
75. Macrophage plasticity and polarization: In vivo veritas10.1172/JCI59643 ↗
76. Macrophages in Tissue Repair, Regeneration, and Fibrosis10.1016/j.immuni.2016.02.015 ↗
77. Interplay between biomaterials and the immune system: Challenges and opportunities in regenerative medicine10.1016/j.actbio.2022.11.003 ↗
78. Extracellular Matrix-Based Strategies for Immunomodulatory Biomaterials Engineering10.1002/adhm.201801578 ↗
79. Interactions Between Immunomodulatory Biomaterials and Immune Microenvironment: Cues for Immunomodulation Strategies in Tissue Repair10.3389/fbioe.2022.820940 ↗
80. Immuno-modulatory biomaterials as anti-inflammatory therapeutics10.1016/j.bcp.2021.114890 ↗
81. Resolvins and protectins in inflammation resolution10.1021/cr100396c ↗
82. Antimicrobial and anti-inflammatory thermo-reversible hydrogel for periodontal delivery10.1016/j.actbio.2020.09.018 ↗
83. Reis, M.B., Pereira, P.A.T., Caetano, G.F., Leite, M.N., Galvao, A.F., Paula-Silva, F.W.G., Frade, M.A.C., and Faccioli, L.H. (2017). Lipoxin A4 encapsulated in PLGA microparticles accelerates wound healing of skin ulcers. PLoS ONE, 12.10.1371/journal.pone.0182381 ↗
84. A multifunctional nanoparticle for efferocytosis and pro-resolving-mediated endometriosis therapy10.1016/j.colsurfb.2022.112893 ↗
85. Modulation of the inflammatory response to chitosan through M2 macrophage polarization using pro-resolution mediators10.1016/j.biomaterials.2014.10.035 ↗
86. Development of an immunomodulatory biomaterial: Using resolvin D1 to modulate inflammation10.1016/j.biomaterials.2015.02.120 ↗
87. Chitosan porous 3D scaffolds embedded with resolvin D1 to improve in vivo bone healing10.1002/jbm.a.36370 ↗
88. Dual delivery of IL-10 and AT-RvD1 from PEG hydrogels polarize immune cells towards pro-regenerative phenotypes10.1016/j.biomaterials.2020.120475 ↗
89. Aspirin-Triggered Resolvin D1-modified materials promote the accumulation of pro-regenerative immune cell subsets and enhance vascular remodeling10.1016/j.actbio.2017.02.020 ↗
90. Regulation of the inflammatory response by vascular grafts modified with Aspirin-Triggered Resolvin D1 promotes blood vessel regeneration10.1016/j.actbio.2019.07.037 ↗
91. Biomimetic anti-inflammatory nano-capsule serves as a cytokine blocker and M2 polarization inducer for bone tissue repair10.1016/j.actbio.2019.11.025 ↗
92. Catechol-chitosan/polyacrylamide hydrogel wound dressing for regulating local inflammation10.1016/j.mtbio.2022.100392 ↗
93. The effect of resolvin D1 on bone regeneration in a rat calvarial defect model10.1002/term.3345 ↗
94. Maresin-2 promotes mucosal repair and has therapeutic potential when encapsulated in thermostable nanoparticles10.1073/pnas.2218162120 ↗
95. Furutani, K., Chen, O., McGinnis, A., Wang, Y., Serhan, C.N., Hansen, T.V., and Ji, R.R. (2022). Novel proresolving lipid mediator mimetic 3-oxa-PD1n-3 docosapentaenoic acid reduces acute and chronic itch by modulating excitatory and inhibitory synaptic transmission and astroglial secretion of lipocalin-2 in mice. Pain.10.1097/j.pain.0000000000002824 ↗
96. Lipoxin A(4) activates ALX/FPR2 receptor to regulate conjunctival goblet cell secretion10.1038/mi.2016.33 ↗
97. Protective actions of aspirin-triggered (17R) resolvin D1 and its analogue, 17R-hydroxy-19-para-fluorophenoxy-resolvin D1 methyl ester, in C5a-dependent IgG immune complex-induced inflammation and lung injury10.4049/jimmunol.1400942 ↗
98. Polymer micelles for the protection and delivery of specialized pro-resolving mediators10.1016/j.ejpb.2023.01.020 ↗
99. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors10.1016/j.mam.2017.03.005 ↗